Ashraf Mohammadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ashraf Mohammadi has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Behnam Alirezaie
Department of Human Viral Vaccines, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization, Karaj, Iran
4 shared publications Abbas Shafyi
3 shared publicationsFatemeh Esna-Ashari
Department of Human Viral Vaccines, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization, Karaj, Iran
3 shared publications- Mohammad Majid Ebrahimi
Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization, Karaj, Iran
3 shared publications - Shahla Shahsavandi
Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization, Karaj, Iran
3 shared publications A Shafyi
Member of scientific board, Human Viral Vaccines Department, Razi Vaccine and Serum Research Institute, Karaj, Iran
2 shared publications
Latest Publications
- Open Access
- 3 May 2026
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 19 (4) , e166803
Evaluation of Humoral Immunity Induced by Commonly Administered COVID-19 Vaccines in Middle-aged Iranians
Background: Using a comparative analysis and assessment approach on a number of vaccine under investigation in a specific group is pertinent to local health policy and to our scientific understanding of vaccine responses. Objectives: In this double-blind, cross-sectional study, the efficacy of two platforms inactivated COVID-19 vaccines (CO-Iran Barekat and Sinopharm) and adenoviral-vector COVID-19 vaccines (AstraZeneca and Sputnik V) most commonly used in the Iranian population was evaluated. The target population was 40 - 60 years old. Humoral immune response evaluated by the production of virus-neutralizing antibodies and immunoglobulin G binding to the receptor-binding domain (RBD). Methods: Four hundred twenty volunteers aged 40 - 60 years were vaccinated with the COVID-19 vaccines including CO-Iran Barekat, Sinopharm, AstraZeneca and Sputnik. After receiving the second dose, the humoral immune response was assessed using a conventional neutralizing antibody assay and IgG ELISA. Results: Recipients of the Barekat and Sinopharm vaccines had negative IgG responses of ~15.3% and ~32.97% respectively, while a negative IgG response in the Sputnik V vaccine group showed 10.58%. No negative IgG response was noted with the AstraZeneca group. In the neutralizing antibody assay against SARS-CoV-2, AstraZeneca, Sputnik V, COV-Iran Barekat and Sinopharm showed effective protection in 87.73%, 59.61%, 54.23% and 35.16% respectively. The S1-IgG and SARS-CoV-2 neutralization responses found with Sinopharm and COV-Iran Barekat were similar to those seen vaccinated individuals. In contrast, the conventional live-virus neutralization titer (cVNT50) in SARS-CoV-2-AstraZeneca vaccines was much higher than any of the other three groups. Also data analysis of adverse vaccine event revealed that injection site pain is the most common adverse event in the four groups. Conclusions: The highest levels of neutralizing antibodies were found with AstraZeneca that further support its higher effective potential for protection to SARS-CoV-2. Antibody levels were measured with ELISA IgG Kits and a conventional neutralizing antibody assay technique.
- 3 May 2026
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 19 (4) , e166803
Open AccessEvaluation of Humoral Immunity Induced by Commonly Administered COVID-19 Vaccines in Middle-aged Iranians
Background: Using a comparative analysis and assessment approach on a number of vaccine under investigation in a specific group is pertinent to local health policy and to our scientific understanding of vaccine responses. Objectives: In this double-blind, cross-sectional study, the efficacy of two platforms inactivated COVID-19 vaccines (CO-Iran Barekat and Sinopharm) and adenoviral-vector COVID-19 vaccines (AstraZeneca and Sputnik V) most commonly used in the Iranian population was evaluated. The target population was 40 - 60 years old. Humoral immune response evaluated by the production of virus-neutralizing antibodies and immunoglobulin G binding to the receptor-binding domain (RBD). Methods: Four hundred twenty volunteers aged 40 - 60 years were vaccinated with the COVID-19 vaccines including CO-Iran Barekat, Sinopharm, AstraZeneca and Sputnik. After receiving the second dose, the humoral immune response was assessed using a conventional neutralizing antibody assay and IgG ELISA. Results: Recipients of the Barekat and Sinopharm vaccines had negative IgG responses of ~15.3% and ~32.97% respectively, while a negative IgG response in the Sputnik V vaccine group showed 10.58%. No negative IgG response was noted with the AstraZeneca group. In the neutralizing antibody assay against SARS-CoV-2, AstraZeneca, Sputnik V, COV-Iran Barekat and Sinopharm showed effective protection in 87.73%, 59.61%, 54.23% and 35.16% respectively. The S1-IgG and SARS-CoV-2 neutralization responses found with Sinopharm and COV-Iran Barekat were similar to those seen vaccinated individuals. In contrast, the conventional live-virus neutralization titer (cVNT50) in SARS-CoV-2-AstraZeneca vaccines was much higher than any of the other three groups. Also data analysis of adverse vaccine event revealed that injection site pain is the most common adverse event in the four groups. Conclusions: The highest levels of neutralizing antibodies were found with AstraZeneca that further support its higher effective potential for protection to SARS-CoV-2. Antibody levels were measured with ELISA IgG Kits and a conventional neutralizing antibody assay technique.
- Open Access
- 16 December 2023
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 18 (5)
Transplacental Transfer Efficiency of SARS-CoV-2-Specific IgG Antibodies in Iranian Seropositive Mothers: A Monocentric Study in Karaj, Iran
Background: Passively acquired maternal antibodies through the placenta and/or breastfeeding may protect neonates against SARS-CoV-2 before they are considered eligible for active immunization. Objectives: This study aimed to determine the concentration and correlation of maternal and cord blood anti-SARS-CoV-2 IgG antibodies in Iranian seropositive women. In this preliminary study, attempts were also made to assess the effects of some variables on the transplacental transfer efficiency. Methods: From September 2021 to November 2021, pregnant women presenting to Kamali Hospital in Karaj, Iran, were enrolled in this monocentric study. The maternal and neonatal demographic characteristics were collected. The maternal and cord blood spike protein-specific antibody levels, measured at delivery (119 paired samples), were evaluated by the enzyme-linked immunosorbent assay (ELISA). Results: Based on the transplacental antibody transfer ratios, the participants were divided into 2 groups: Transfer ratio ≤ 1 (n = 53) and transfer ratio > 1 (n = 66). The results revealed that anti-SARS-CoV-2 IgG antibodies were transferred across the placenta in all seropositive pregnant Iranian women, and a significant correlation was found between maternal and cord blood-specific IgG antibody levels (r = 0.9646; P < 0.05). A relatively efficient transplacental transfer ratio was observed in Iranian seropositive women (transfer ratio > 1 in 66 out of 119 individuals; 55.46%). Although there were significant differences in the transplacental transfer ratio regarding the neonatal birth weight and maternal body mass index (BMI), more extensive investigations with a larger sample size are needed to confirm the significant association of these variables with the transplacental transfer efficiency of specific SARS-CoV-2 IgG antibodies. Conclusions: The present study highlighted the importance of vaccination during pregnancy to improve neonatal immune responses against SARS-CoV-2.
- 16 December 2023
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 18 (5)
Open AccessTransplacental Transfer Efficiency of SARS-CoV-2-Specific IgG Antibodies in Iranian Seropositive Mothers: A Monocentric Study in Karaj, Iran
Background: Passively acquired maternal antibodies through the placenta and/or breastfeeding may protect neonates against SARS-CoV-2 before they are considered eligible for active immunization. Objectives: This study aimed to determine the concentration and correlation of maternal and cord blood anti-SARS-CoV-2 IgG antibodies in Iranian seropositive women. In this preliminary study, attempts were also made to assess the effects of some variables on the transplacental transfer efficiency. Methods: From September 2021 to November 2021, pregnant women presenting to Kamali Hospital in Karaj, Iran, were enrolled in this monocentric study. The maternal and neonatal demographic characteristics were collected. The maternal and cord blood spike protein-specific antibody levels, measured at delivery (119 paired samples), were evaluated by the enzyme-linked immunosorbent assay (ELISA). Results: Based on the transplacental antibody transfer ratios, the participants were divided into 2 groups: Transfer ratio ≤ 1 (n = 53) and transfer ratio > 1 (n = 66). The results revealed that anti-SARS-CoV-2 IgG antibodies were transferred across the placenta in all seropositive pregnant Iranian women, and a significant correlation was found between maternal and cord blood-specific IgG antibody levels (r = 0.9646; P < 0.05). A relatively efficient transplacental transfer ratio was observed in Iranian seropositive women (transfer ratio > 1 in 66 out of 119 individuals; 55.46%). Although there were significant differences in the transplacental transfer ratio regarding the neonatal birth weight and maternal body mass index (BMI), more extensive investigations with a larger sample size are needed to confirm the significant association of these variables with the transplacental transfer efficiency of specific SARS-CoV-2 IgG antibodies. Conclusions: The present study highlighted the importance of vaccination during pregnancy to improve neonatal immune responses against SARS-CoV-2.
- Open Access
- 1 December 2022
- Published by Apex Publishing in Vaccine Research
- Vol. 9 (2) , 37-41
Yeast-Produced S1 Recombinant Protein of SARS-CoV-2
Introduction: COVID-19 pandemic caused by the emerging SARS-CoV-2, being the cause of COVID-19, leads to acute respiratory syndrome and is a vital threat to global health and the economy since it was identified in late December 2019 in China. Due to the limitations and long-time of vaccine production, most countries were ...
- 1 December 2022
- Published by Apex Publishing in Vaccine Research
- Vol. 9 (2) , 37-41
Open AccessYeast-Produced S1 Recombinant Protein of SARS-CoV-2
Introduction: COVID-19 pandemic caused by the emerging SARS-CoV-2, being the cause of COVID-19, leads to acute respiratory syndrome and is a vital threat to global health and the economy since it was identified in late December 2019 in China. Due to the limitations and long-time of vaccine production, most countries were ...
- Open Access
- 19 September 2022
- Published by Brieflands in International Journal of Cancer Management
- Vol. 15 (9)
Isolation and Characterization of a Discrete Genetically Homogeneous Viral Subpopulation of Mumps Virus RS-12 Strain with Superior Oncolytic Potency Compared to Its Progenitor Virus
Background: Oncolytic virotherapy can serve as a novel therapeutic strategy in oncology. In this study, we aimed to evaluate the oncolytic activity of the mumps virus RS-12 strain after its adaptation to cancer cells via serial passaging. Methods: To adapt the RS-12 strain-based vaccine to cancer cells, it was passaged eight times in the HT1080 cell line and was isolated via two terminal endpoint dilutions. The genetic homogeneity of isolated cancer cell-adapted RS-12 variant was confirmed by direct sequencing of regions, encompassing four known heterogeneous genomic positions. The in vitro cytotoxic effects of viruses was assessed in two different cancer cell lines using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The apoptosis-inducing effects of the cancer cell-adapted variant and its parental virus on cancer cells were quantified by flow cytometry. Results: According to the chromatograms, the RS-12 strain vaccine seed exhibited two peaks at the genomic nucleotide positions 1591, 2417, 3774, and 12977. On the contrary, cancer cell-adapted RS-12, isolated by terminal endpoint serial dilutions, contained no viral subpopulations in these positions. A significant improvement was observed in the oncolytic potency of our cancer cell-adapted variant compared to its parental virus vaccine seed in vitro. Besides, the variant efficiently induced apoptosis in the human fibrosarcoma and adenocarcinoma cell lines. Conclusions: Considering the increased oncolytic potency and apoptosis-inducing capacity of this variant in cancer cells, it can be a promising option for future experiments.
- 19 September 2022
- Published by Brieflands in International Journal of Cancer Management
- Vol. 15 (9)
Open AccessIsolation and Characterization of a Discrete Genetically Homogeneous Viral Subpopulation of Mumps Virus RS-12 Strain with Superior Oncolytic Potency Compared to Its Progenitor Virus
Background: Oncolytic virotherapy can serve as a novel therapeutic strategy in oncology. In this study, we aimed to evaluate the oncolytic activity of the mumps virus RS-12 strain after its adaptation to cancer cells via serial passaging. Methods: To adapt the RS-12 strain-based vaccine to cancer cells, it was passaged eight times in the HT1080 cell line and was isolated via two terminal endpoint dilutions. The genetic homogeneity of isolated cancer cell-adapted RS-12 variant was confirmed by direct sequencing of regions, encompassing four known heterogeneous genomic positions. The in vitro cytotoxic effects of viruses was assessed in two different cancer cell lines using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The apoptosis-inducing effects of the cancer cell-adapted variant and its parental virus on cancer cells were quantified by flow cytometry. Results: According to the chromatograms, the RS-12 strain vaccine seed exhibited two peaks at the genomic nucleotide positions 1591, 2417, 3774, and 12977. On the contrary, cancer cell-adapted RS-12, isolated by terminal endpoint serial dilutions, contained no viral subpopulations in these positions. A significant improvement was observed in the oncolytic potency of our cancer cell-adapted variant compared to its parental virus vaccine seed in vitro. Besides, the variant efficiently induced apoptosis in the human fibrosarcoma and adenocarcinoma cell lines. Conclusions: Considering the increased oncolytic potency and apoptosis-inducing capacity of this variant in cancer cells, it can be a promising option for future experiments.
- Open Access
- 27 May 2022
- Published by Scientific Archives
- Vol. 3 (1) , 1-18
A New Isolated Local Varicella Virus: Isolation, Identification, Comparative Growth Characteristics and Immunological Evaluation in an Animal Model
A panel of 4 different cell lines was optimized for isolation, identification, and authentication of a varicella zoster virus from a swab sample of an 8-year-old boy suspected to varicella zoster infection. The system enabled highly efficient and rapid isolation of viruses in 33°C by serial sub culturing to more than 25 passages. The technique relies on isolation of viral genes by increasing the number of particles that are statistically represented in cell culture and verified by cell culture infectious dose 50% assay, fluorescence amidites- real time- polymerase chain reaction, and the varicella-zoster virus immediate-early protein 62 antibody in immunofluorescence test, using vaccinal Oka as attenuated varicella zoster virus golden standard. The viral genes (ORF38, ORF54) confirmed the new isolate as varicella zoster virus and revealed the amino acid sequence of viral-encoded proteins after 27 passages, identical with positive control virus, in restriction fragment length polymorphism polymerase chain reaction test. Utilization of successive serial passages at temperatures lower than the normal body temperature would reduce the virus virulence and directly cause virus attenuation
- 27 May 2022
- Published by Scientific Archives
- Vol. 3 (1) , 1-18
Open AccessA New Isolated Local Varicella Virus: Isolation, Identification, Comparative Growth Characteristics and Immunological Evaluation in an Animal Model
A panel of 4 different cell lines was optimized for isolation, identification, and authentication of a varicella zoster virus from a swab sample of an 8-year-old boy suspected to varicella zoster infection. The system enabled highly efficient and rapid isolation of viruses in 33°C by serial sub culturing to more than 25 passages. The technique relies on isolation of viral genes by increasing the number of particles that are statistically represented in cell culture and verified by cell culture infectious dose 50% assay, fluorescence amidites- real time- polymerase chain reaction, and the varicella-zoster virus immediate-early protein 62 antibody in immunofluorescence test, using vaccinal Oka as attenuated varicella zoster virus golden standard. The viral genes (ORF38, ORF54) confirmed the new isolate as varicella zoster virus and revealed the amino acid sequence of viral-encoded proteins after 27 passages, identical with positive control virus, in restriction fragment length polymorphism polymerase chain reaction test. Utilization of successive serial passages at temperatures lower than the normal body temperature would reduce the virus virulence and directly cause virus attenuation
- Open Access
A new isolated local varicella virus: isolation, identification, comparative growth characteristics and immunological evaluation on an animal model
A panel of 4 different cell lines was optimized for isolation, identification, and authentication of a VZV virus from a swab sample of an 8-year-old boy suspected to varicella zoster infection. The system enabled highly efficient and rapid isolation of viruses in 33°C by serial sub culturing to more than 25 passages. The technique relies on isolation of viral genes by increasing the number of particles that are statistically represented in cell culture and verified by CCID 50 , FAM-RT-PCR, and IE62 antibody in IF test. The viral genes (ORF38, ORF54) confirmed the new isolate as VZV and revealed the amino acid sequence of viral-encoded proteins after 27 passages, identical with positive control virus, in RFLP-PCR test. Utilization of successive serial passages at temperatures lower than the normal body temperature would reduce the virus virulence and directly cause virus attenuation. As a result, the attenuated virus is adapted to growth in vitro and presented higher replication at 33°C. Our goal was to determine if the targeted virus with a large double-stranded DNA genome, varicella virus, is isolated and can be attenuated by cold adapting in vitro, Using vOka as attenuated VZV golden standard, in two quantitative tests, including CCID50 and FAM-RT-PCR. Finally, when compared with the local isolated virus, these results were strongly confirmed. We recorded plaque forming assay to show phenotypic changing which encodes the attenuation regarding size of plaque. Although in plaque forming assay, the size of plaque seemed smaller at first glance, the statistical distribution of the plaque size did not show any change between the virus in the first and last passages. In cell culture, the local VZV isolated viruses formed clear plaques and grew to higher titers compared with lower passages as parental virus.Due to lack of access to human fetal lung cells (MRC-5) and an alternative to vaccine production in the future, a new authenticated local foreskin cell substrate (RFSC) was used for virus cultivation. In comparison to, MRC-5-optimized and cloned-viruses replicated in vitro with kinetics that were similar to those of the RFSC. Laboratory animals that were infected with the optimized virus fluid as vaccine showed a good neutralization antibody against local VZV isolated as compared to vOka as control positive virus. These results demonstrate that the virus isolated from swab sample was authenticated as VZV virus, and this cold adapted attenuated virus may be an applicable candidate for future plan. Author summary: We used different cell substrates for isolation, identification, and attenuation of a new local VZV virus from vesicle swab of suspected patient to varicella zoster diseases. The technique involves serial sub culturing of virus in cell culture. Our goal was to determine if the targeted virus with a large double-stranded DNA genome, varicella virus, is isolated and can be attenuated by cold adapting in vitro, using vOka as attenuated VZV golden standard, The virus was cloned and purified by serial dilution cloning and plaque assay. Different techniques were used regarding verification as differentiation from other members in family, potency, and sterility for isolated virus. The virus can grow well in new local foreskin cell substrate and produce good titre as compared with MRC-5. The isolated VZV potentially induced neutralization antibody in animal model. The results of our study imply that local VZV might be an applicable isolate for future plan in research and developing a varicella vaccine.
Open AccessA new isolated local varicella virus: isolation, identification, comparative growth characteristics and immunological evaluation on an animal model
A panel of 4 different cell lines was optimized for isolation, identification, and authentication of a VZV virus from a swab sample of an 8-year-old boy suspected to varicella zoster infection. The system enabled highly efficient and rapid isolation of viruses in 33°C by serial sub culturing to more than 25 passages. The technique relies on isolation of viral genes by increasing the number of particles that are statistically represented in cell culture and verified by CCID 50 , FAM-RT-PCR, and IE62 antibody in IF test. The viral genes (ORF38, ORF54) confirmed the new isolate as VZV and revealed the amino acid sequence of viral-encoded proteins after 27 passages, identical with positive control virus, in RFLP-PCR test. Utilization of successive serial passages at temperatures lower than the normal body temperature would reduce the virus virulence and directly cause virus attenuation. As a result, the attenuated virus is adapted to growth in vitro and presented higher replication at 33°C. Our goal was to determine if the targeted virus with a large double-stranded DNA genome, varicella virus, is isolated and can be attenuated by cold adapting in vitro, Using vOka as attenuated VZV golden standard, in two quantitative tests, including CCID50 and FAM-RT-PCR. Finally, when compared with the local isolated virus, these results were strongly confirmed. We recorded plaque forming assay to show phenotypic changing which encodes the attenuation regarding size of plaque. Although in plaque forming assay, the size of plaque seemed smaller at first glance, the statistical distribution of the plaque size did not show any change between the virus in the first and last passages. In cell culture, the local VZV isolated viruses formed clear plaques and grew to higher titers compared with lower passages as parental virus.Due to lack of access to human fetal lung cells (MRC-5) and an alternative to vaccine production in the future, a new authenticated local foreskin cell substrate (RFSC) was used for virus cultivation. In comparison to, MRC-5-optimized and cloned-viruses replicated in vitro with kinetics that were similar to those of the RFSC. Laboratory animals that were infected with the optimized virus fluid as vaccine showed a good neutralization antibody against local VZV isolated as compared to vOka as control positive virus. These results demonstrate that the virus isolated from swab sample was authenticated as VZV virus, and this cold adapted attenuated virus may be an applicable candidate for future plan. Author summary: We used different cell substrates for isolation, identification, and attenuation of a new local VZV virus from vesicle swab of suspected patient to varicella zoster diseases. The technique involves serial sub culturing of virus in cell culture. Our goal was to determine if the targeted virus with a large double-stranded DNA genome, varicella virus, is isolated and can be attenuated by cold adapting in vitro, using vOka as attenuated VZV golden standard, The virus was cloned and purified by serial dilution cloning and plaque assay. Different techniques were used regarding verification as differentiation from other members in family, potency, and sterility for isolated virus. The virus can grow well in new local foreskin cell substrate and produce good titre as compared with MRC-5. The isolated VZV potentially induced neutralization antibody in animal model. The results of our study imply that local VZV might be an applicable isolate for future plan in research and developing a varicella vaccine.
- Open Access
- 28 September 2020
- Published by Brieflands in International Journal of Cancer Management
- Vol. 13 (9)
Intrinsic Oncolytic Activity of Hoshino Mumps Virus Vaccine Strain Against Human Fibrosarcoma and Cervical Cancer Cell Lines
Background: The use of oncolytic viruses as therapeutic agents is a promising treatment for various human cancers. Several viruses have been extensively examined to achieve tumor cell death. Objectives: This study aimed at evaluating the natural oncolytic activity of mumps Hoshino vaccine strain against two human cancer cell lines, that is, HT1080 fibrosarcoma and HeLa cervical adenocarcinoma cell lines. Methods: The cytolytic activity of the virus was evaluated using an MTT assay. Apoptosis was detected by Annexin-V/propidium iodide (PI) staining and analyzed via flow cytometry. To indicate viral replication in vivo, nude mice with HeLa heterografts were treated with the Hoshino strain of mumps virus. Results: It was found that human fibrosarcoma and cervical cells were more sensitive to the mumps Hoshino strain, even at a very low multiplicity of infection (MOI) compared to normal human diploid cells. The results also showed that the Hoshino strain induced apoptosis in both cancer cells. A preliminary in vivo study revealed the significant suppression of tumor growth in the group treated with the mumps Hoshino strain compared to the control group. Conclusions: The Hoshino vaccine strain of mumps virus showed promising oncolytic activities against human fibrosarcoma and cervical adenocarcinoma cells.
- 28 September 2020
- Published by Brieflands in International Journal of Cancer Management
- Vol. 13 (9)
Open AccessIntrinsic Oncolytic Activity of Hoshino Mumps Virus Vaccine Strain Against Human Fibrosarcoma and Cervical Cancer Cell Lines
Background: The use of oncolytic viruses as therapeutic agents is a promising treatment for various human cancers. Several viruses have been extensively examined to achieve tumor cell death. Objectives: This study aimed at evaluating the natural oncolytic activity of mumps Hoshino vaccine strain against two human cancer cell lines, that is, HT1080 fibrosarcoma and HeLa cervical adenocarcinoma cell lines. Methods: The cytolytic activity of the virus was evaluated using an MTT assay. Apoptosis was detected by Annexin-V/propidium iodide (PI) staining and analyzed via flow cytometry. To indicate viral replication in vivo, nude mice with HeLa heterografts were treated with the Hoshino strain of mumps virus. Results: It was found that human fibrosarcoma and cervical cells were more sensitive to the mumps Hoshino strain, even at a very low multiplicity of infection (MOI) compared to normal human diploid cells. The results also showed that the Hoshino strain induced apoptosis in both cancer cells. A preliminary in vivo study revealed the significant suppression of tumor growth in the group treated with the mumps Hoshino strain compared to the control group. Conclusions: The Hoshino vaccine strain of mumps virus showed promising oncolytic activities against human fibrosarcoma and cervical adenocarcinoma cells.
- Open Access
- 15 April 2019
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 17 (6) , 586-593
Induction of Immune Response and Protective Immunity by a Local Isolated Varicella Virus in Animal Model: A Future Candidates for Vaccine Production
Preparation of the indigenous varicella zoster vaccine could significantly reduce the disease burden of varicella zoster virus especially in immunosuppressed children. To achieve this goal, the varicella zoster virus was isolated from an 8 years boy infected with chicken pox. The virus was cultivated in sensitive cell line and determined varicella zoster. The adaptation and attenuation of virus was carried out after several passages in MRC-5 cell culture, Primary Guinea pig embryo fibroblast cell culture and again switching in MRC-5 cell culture. The challenged of vaccine dose was found 3LogCCID50. Following two doses of immunization in guinea pigs via inoculated cell culture-fluid attenuated- local isolated VZV at zero and 14 day, the humoral immune response, varicella-zoster virus (VZV) IgG and IgM were determined using enzyme-linked Immunosorbent and seroneutralization assays at 7, 14, 21, 30, 60, 90.120 days after receiving of the first and second dose of vaccine. The results of immunization showed good 93% seroconversion in guinea pig which compared with vOKa vaccine was not significant (p<0.05). The prepared attenuate varicella zoster virus promising a candidate Virus for our future plan to vaccine production.
- 15 April 2019
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 17 (6) , 586-593
Open AccessInduction of Immune Response and Protective Immunity by a Local Isolated Varicella Virus in Animal Model: A Future Candidates for Vaccine Production
Preparation of the indigenous varicella zoster vaccine could significantly reduce the disease burden of varicella zoster virus especially in immunosuppressed children. To achieve this goal, the varicella zoster virus was isolated from an 8 years boy infected with chicken pox. The virus was cultivated in sensitive cell line and determined varicella zoster. The adaptation and attenuation of virus was carried out after several passages in MRC-5 cell culture, Primary Guinea pig embryo fibroblast cell culture and again switching in MRC-5 cell culture. The challenged of vaccine dose was found 3LogCCID50. Following two doses of immunization in guinea pigs via inoculated cell culture-fluid attenuated- local isolated VZV at zero and 14 day, the humoral immune response, varicella-zoster virus (VZV) IgG and IgM were determined using enzyme-linked Immunosorbent and seroneutralization assays at 7, 14, 21, 30, 60, 90.120 days after receiving of the first and second dose of vaccine. The results of immunization showed good 93% seroconversion in guinea pig which compared with vOKa vaccine was not significant (p<0.05). The prepared attenuate varicella zoster virus promising a candidate Virus for our future plan to vaccine production.
- Open Access
- 5 May 2018
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 11 (5)
Measles Vaccines in Iran: A 50-Year Review of Vaccine Development, Production and Effectiveness (1967 - 2017)
Context: Information on the measles vaccine is important for future measles control policies. Vaccination history and laboratory confirmation during the development of the AIK measles vaccine in Iran is surveyed in this article. In addition, the production results and effectiveness of the Razi AIK-C/MRC-5 measles strain are compared with other vaccine strains. Evidence Acquisition: The current study was carried out to aim local measles vaccine manufacturing and consequences of that in Iran, using various search engines. Almost complete search carried out in medical databases including PubMed, Scopus, Web of Science, Scientific Information Database, IranMedex, Magiran and Google Scholar. Results: The morbidity rate of measles during the pre-vaccine era of this disease was 10,000 cases/year in 1970 - 1972. In 1997, the rate was 24 in 1000 cases. After using the high quality Razi measles vaccine between 1995 and 2013, the number of measles-positive cases declined to a maximum of 35 cases per year, while the country’s population increased by more than 2.5 times. The median of the Razi measles vaccine efficacy (VE) was > 92.1% compared with that of the pre-vaccine era. For patients who received 2 doses of the measles vaccine at either 6 and 12 months or 9 and 18 months of age, the median VEs were > 90.0% (interquartile range [IQR], 83% - 97%) and 92.0% (IQR, 86% - 98%), respectively. The age at vaccination and strain type used in the vaccines are reviewed in this article. Conclusion: The effectiveness of the local Razi measles vaccine resulted in a significant decline in measles mortality and morbidity in Iran. Two doses of the Razi measles (MR) or measles combination (MMR) vaccine provided excellent protection against measles. The seroprevalance of the measles vaccine in Iran revealed that more than 90% of Iranians are seropositive for the measles virus. Keywords: Measles; Vaccine; Iran
- 5 May 2018
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 11 (5)
Open AccessMeasles Vaccines in Iran: A 50-Year Review of Vaccine Development, Production and Effectiveness (1967 - 2017)
Context: Information on the measles vaccine is important for future measles control policies. Vaccination history and laboratory confirmation during the development of the AIK measles vaccine in Iran is surveyed in this article. In addition, the production results and effectiveness of the Razi AIK-C/MRC-5 measles strain are compared with other vaccine strains. Evidence Acquisition: The current study was carried out to aim local measles vaccine manufacturing and consequences of that in Iran, using various search engines. Almost complete search carried out in medical databases including PubMed, Scopus, Web of Science, Scientific Information Database, IranMedex, Magiran and Google Scholar. Results: The morbidity rate of measles during the pre-vaccine era of this disease was 10,000 cases/year in 1970 - 1972. In 1997, the rate was 24 in 1000 cases. After using the high quality Razi measles vaccine between 1995 and 2013, the number of measles-positive cases declined to a maximum of 35 cases per year, while the country’s population increased by more than 2.5 times. The median of the Razi measles vaccine efficacy (VE) was > 92.1% compared with that of the pre-vaccine era. For patients who received 2 doses of the measles vaccine at either 6 and 12 months or 9 and 18 months of age, the median VEs were > 90.0% (interquartile range [IQR], 83% - 97%) and 92.0% (IQR, 86% - 98%), respectively. The age at vaccination and strain type used in the vaccines are reviewed in this article. Conclusion: The effectiveness of the local Razi measles vaccine resulted in a significant decline in measles mortality and morbidity in Iran. Two doses of the Razi measles (MR) or measles combination (MMR) vaccine provided excellent protection against measles. The seroprevalance of the measles vaccine in Iran revealed that more than 90% of Iranians are seropositive for the measles virus. Keywords: Measles; Vaccine; Iran
- Open Access
- 1 November 2013
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 6 (9)
Replication Efficiency of Influenza A Virus H9N2: A Comparative Analysis Between Different Origin Cell Types
Background: Efficient isolation and detection of low pathogenic avian influenza viruses from surveillance samples continues to be a high priority. Currently, the new cell lines are considered for supporting the replication to high virus strains titers. Objectives: The replication efficiency of a low pathogenic avian influenza virus in different origin cells was evaluated under different conditions. Materials and Methods: Chicken embryo fibroblast (CEF) cell and human alveolar epithelial cell line (A549) were infected with H9N2 at a multiplicity of infection of 0.1. The amount of infectious virus released into the cell culture supernatants at various post-infection time intervals were tittered by tissue culture infectious dose (TCID50) assay. The impact of these cells adaptation was investigated by determination the virus genes nucleotide sequences. Results: The influenza virus infectivity was not significant difference in these cells in the presence of trypsin. The results of fusion assay and determination of cellular protease confirmed that A549 cells support virus entry with or without supplemental trypsin. However, the H9N2 virus showed lower titer and infectivity in the trypsin–free infected A549 cells within longer time. The comparative sequence analysis indicated several simultaneously nucleotide substitutions were occurred in NA of the virus replicated in A549 cells resulted in two fixed amino acid changes at positions G320 to A and G414 to A up to the fifth passage. Conclusions: After seven consecutive passages of both cell cultures, the H9N2 virus showed similar antigenicity, also no change on viral titer level and virus replication behavior in adaptation was found. The results highlighted the use of A549 cells for efficient virus isolation. Keywords: Influenza virus; H9N2 subtype; replication kinetic
- 1 November 2013
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 6 (9)
Open AccessReplication Efficiency of Influenza A Virus H9N2: A Comparative Analysis Between Different Origin Cell Types
Background: Efficient isolation and detection of low pathogenic avian influenza viruses from surveillance samples continues to be a high priority. Currently, the new cell lines are considered for supporting the replication to high virus strains titers. Objectives: The replication efficiency of a low pathogenic avian influenza virus in different origin cells was evaluated under different conditions. Materials and Methods: Chicken embryo fibroblast (CEF) cell and human alveolar epithelial cell line (A549) were infected with H9N2 at a multiplicity of infection of 0.1. The amount of infectious virus released into the cell culture supernatants at various post-infection time intervals were tittered by tissue culture infectious dose (TCID50) assay. The impact of these cells adaptation was investigated by determination the virus genes nucleotide sequences. Results: The influenza virus infectivity was not significant difference in these cells in the presence of trypsin. The results of fusion assay and determination of cellular protease confirmed that A549 cells support virus entry with or without supplemental trypsin. However, the H9N2 virus showed lower titer and infectivity in the trypsin–free infected A549 cells within longer time. The comparative sequence analysis indicated several simultaneously nucleotide substitutions were occurred in NA of the virus replicated in A549 cells resulted in two fixed amino acid changes at positions G320 to A and G414 to A up to the fifth passage. Conclusions: After seven consecutive passages of both cell cultures, the H9N2 virus showed similar antigenicity, also no change on viral titer level and virus replication behavior in adaptation was found. The results highlighted the use of A549 cells for efficient virus isolation. Keywords: Influenza virus; H9N2 subtype; replication kinetic